Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

by · The Cerbat Gem

Analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX opened at $0.97 on Friday. Akari Therapeutics has a 52-week low of $0.90 and a 52-week high of $4.40. The firm has a 50 day moving average price of $1.63 and a 200 day moving average price of $2.72.

About Akari Therapeutics

(Get Free Report)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.

Read More